We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · January 27, 2022

Long-Term Outcomes and Genomic Correlates of Response After Neoadjuvant Chemotherapy ± Carboplatin and Bevacizumab in TNBC

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer
J. Clin. Oncol 2022 Jan 19;[EPub Ahead of Print], JH Shepherd, K Ballman, MC Polley, JD Campbell, C Fan, S Selitsky, A Fernandez-Martinez, JS Parker, KA Hoadley, Z Hu, Y Li, MG Soloway, PA Spears, B Singh, SM Tolaney, G Somlo, ER Port, C Ma, C Kuzma, E Mamounas, M Golshan, JR Bellon, D Collyar, OM Hahn, CA Hudis, EP Winer, A Partridge, T Hyslop, LA Carey, CM Perou, WM Sikov

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading